Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer

Author： Nelson Valerie   Altman Jessica K   Platanias Leonidas C  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.6, 2013-09, pp. : 715-722

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of the mammalian target of rapamycin

By Dancey Janet E  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 3, 2005-03 ,pp. : 313-328

Informa Healthcare

Access to resources Recommend Favorite

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer

By Albert Sébastien   Serova Maria   Dreyer Chantal   Sablin Marie-Paule   Faivre Sandrine   Raymond Eric  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 8, 2010-08 ,pp. : 919-930

Informa Healthcare

Access to resources Recommend Favorite

Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents

By  

Current Cancer Drug Targets, Vol. 4, Iss. 8, 2004-12 ,pp. : 621-635

Bentham Science Publishers

Access to resources Recommend Favorite

Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment

By Kahan Barry  

Expert Opinion on Drug Safety, Vol. 10, Iss. 5, 2011-09 ,pp. : 727-749

Informa Healthcare

Access to resources Recommend Favorite

Current and future directions in mammalian target of rapamycin inhibitors development

By Fasolo Angelica   Sessa Cristiana  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 3, 2011-03 ,pp. : 381-394

Informa Healthcare

Access to resources Recommend Favorite